Endo will pay up to $637M for Indevus
In a bid to break out of its pain therapy niche, Endo Pharmaceuticals agreed to pay up to $637 million to acquire Indevus Pharmaceuticals. Indevus shareholders get $370 million of that now and up to $267 million more if a series of discovery and commercial milestones are hit. Report![]() | ![]() |
Feature
FierceBiotech's most popular stories of 2008
With 2008 behind us, we'd like to take a look back at the stories and special reports our readers found most interesting over the past year. Unlike the 2007 list, which was dominated by Pfizer news, 2008's top stories covered a mixed bag of topics, ranging from breakthroughs at ACT and Follica to the ongoing financial problems plaguing the biotech industry. ArticleEmerging Drug Developer
Synta Pharmaceuticals
The folks at Synta Pharmaceuticals know how to end a year with a bang. While most people were preparing for the Christmas and New Year's holiday bash, Synta was finalizing a development deal worth potentially $1 billion with Roche. Significantly, the deal covers some of its preclinical work and will include up to three compounds targeting calcium release-activated calcium modulator channels aimed at inflammatory diseases. ArticleReport
Roche, Synta ink $1B deal
Lexington, MA-based Synta Pharmaceuticals and Roche have signed a licensing deal for preclinical anti-inflammatory compound, according to an SEC filing. Synta gets $25 million up front and up to $1 billion in milestone payments if the drug makes it to market. ArticlePress Releases
- CellCentric and Takeda Collaborate on Epigenetic Programme
- Court Rules in Favor of Medtronic in Fidelis Litigation
- Advaxis' Phase II Clinical Trial "HOLD" Lifted
- G. Steven Burrill predicts what's ahead for biotech in 2009
- Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
- Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds




